Bioporto AS (OCSE:BIOPOR) ROCE %: -114.96% (As of Dec. 2025)


OCSE:BIOPOR Bioporto AS OCSE:BIOPOR
69 GF Score
Price kr1.11
GF Value kr1.24
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioporto AS ROCE %?

Bioporto AS OCSE:BIOPOR -2.21% 69 ROCE % is -114.96% as of Dec. 2025. GuruFocus rates OCSE:BIOPOR with a GF Score™ of 69/100 and a GF Value™ of kr1.24 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bioporto AS's annualized ROCE % for the quarter that ended in Dec. 2025 was -114.96%.

Bioporto AS  (OCSE:BIOPOR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bioporto AS ROCE % Related Terms

Bioporto AS ROCE % Historical Data

* Premium members only.

The historical data trend for Bioporto AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS ROCE % Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -75.90 -119.97 -85.34 -104.67 -122.07

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.64 -197.48 -130.60 -177.67 -114.96
OCSE:BIOPOR
69GF Score
Bioporto AS OCSE:BIOPOR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioporto AS ROCE % Calculation

Bioporto AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-87.07/( ( (95.984 - 20.388) + (93.182 - 26.124) )/ 2 )
=-87.07/( (75.596+67.058)/ 2 )
=-87.07/71.327
=-122.07 %

Bioporto AS's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-61.608/( ( (68.09 - 27.967) + (93.182 - 26.124) )/ 2 )
=-61.608/( ( 40.123 + 67.058 )/ 2 )
=-61.608/53.5905
=-114.96 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -114.96% mean?
Bioporto AS (OCSE:BIOPOR) has a ROCE % of -114.96% as of Dec. 2025.
Is Bioporto AS's ROCE % too high?
Bioporto AS's current ROCE % is -114.96%. Overall, Bioporto AS has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's ROCE % compare to TMO and DHR?
Bioporto AS's ROCE % of -114.96% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Bioporto AS's current ROCE % is -114.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.11 — trading 10.9% below its estimated fair value. The current ROCE % is -114.96%. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current ROCE % is -114.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of kr1.11 is trading 10.9% below its estimated GF Value™ of kr1.24. GuruFocus considers Bioporto AS to be Modestly Undervalued.

Key valuation signals for OCSE:BIOPOR:

  • ROCE %: -114.96%
  • GF Value™: kr1.24 vs. price of kr1.11 (10.9% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score

Get the complete analysis for OCSE:BIOPOR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.11
Price
kr1.24
GF Value